Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics ... today announced corporate updates and financial results for the year ended December 31, 2024. “In 2024, we made substantial ...

compared to $7.5 million for the year ended December 31, 2023. Net Loss: Marker reported a net loss of $10.7 million for the year ended December 31, 2024, compared to a net loss of $8.2 million ...

compared to $7.5 million for the year ended December 31, 2023. Net Loss: Marker reported a net loss of $10.7 million for the year ended December 31, 2024, compared to a net loss of $8.2 million for ...